Global Coagulation Factor VIIa Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Coagulation Factor VIIa Market Research Report 2024
Recombinant activated factor VII (rFVIIa) binds to exposed tissue factor at the place of tissue and vascular injury. Thrombin generated by this process activates platelets and the coagulation cascade.
According to Mr Accuracy reports new survey, global Coagulation Factor VIIa market is projected to reach US$ 1529.8 million in 2029, increasing from US$ 1179.9 million in 2022, with the CAGR of 3.7% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Coagulation Factor VIIa market research.
Due to the COVID-19 pandemic, the global Recombinant Human Coagulation VIIa market size is estimated to be worth US$ 1180 million in 2022 and is forecast to a readjusted size of US$ 1467 million by 2028 with a CAGR of 3.7% during the forecast period 2022-2028. Market driver is mainly rising number of hemophilia patients across the world. Recombinant coagulation factors, as opposed to plasma-derived counterparts, consume a very low risk for transfer of infectious diseases and their use would eliminate the risk of infection from viruses such as the human immunodeficiency virus and hepatitis C. The advancement of recombinant coagulation factors has been a major importance in hemophilia care promising nearly complete safety of individuals from the risk of transmitted infections.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Coagulation Factor VIIa market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Novo Nordisk
LFB SA HEMA Biologics
AryoGen Pharmed
GENERIUM
Segment by Type
Prefilled Syringe
Vial
Congenital Hemophilia
Acquired Hemophilia
Other
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Coagulation Factor VIIa report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Coagulation Factor VIIa market is projected to reach US$ 1529.8 million in 2029, increasing from US$ 1179.9 million in 2022, with the CAGR of 3.7% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Coagulation Factor VIIa market research.
Due to the COVID-19 pandemic, the global Recombinant Human Coagulation VIIa market size is estimated to be worth US$ 1180 million in 2022 and is forecast to a readjusted size of US$ 1467 million by 2028 with a CAGR of 3.7% during the forecast period 2022-2028. Market driver is mainly rising number of hemophilia patients across the world. Recombinant coagulation factors, as opposed to plasma-derived counterparts, consume a very low risk for transfer of infectious diseases and their use would eliminate the risk of infection from viruses such as the human immunodeficiency virus and hepatitis C. The advancement of recombinant coagulation factors has been a major importance in hemophilia care promising nearly complete safety of individuals from the risk of transmitted infections.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Coagulation Factor VIIa market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Novo Nordisk
LFB SA HEMA Biologics
AryoGen Pharmed
GENERIUM
Segment by Type
Prefilled Syringe
Vial
Segment by Application
Congenital Hemophilia
Acquired Hemophilia
Other
Consumption by Region
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Coagulation Factor VIIa report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices